Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer
The Effect, Safety and Pharmacoeconomics of First or Second Level-prophylactic Use of PEG-rhG-CSF in Breast Cancer Patients With Medium-high Risk of Febrile Neutropenia During Chemotherapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Hongjian Yang, MD
- Phone Number: 057188122001
- Email: yhjzlyy@163.com
Study Contact Backup
- Name: Haiyan Xu, MD
- Email: xuhy@zjcc.org.cn
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- provision of informed consent
- stage I-III, invasive breast cancer
- accept at least 4 cycles of chemotherapy
- ECOG score 0-2
- with medium-high risk of FN according to researchers
Exclusion Criteria:
- accepted stem cell or bone marrow transplant
- undergoing any other clinical trial
- uncontrolled infection, temperature≥38℃
- per-week scheme chemotherapy
- concurrent with radiotherapy
- allergic conditions
- sever organ dysfunction
- uncontrolled diabetes
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PEGCSF first level prophylactic use
The first level prophylactic use of PEG-rhG-CSF.
The Prophylactic use of PEG-rhG-CSF in all cycles of chemotherapy.
|
6mg (≥45kg) or 3mg (<45kg) i.h.
once 24h after chemotherapy in all cycles of chemotherapy
Other Names:
|
|
PEGCSF second level prophylactic use
The second level prophylactic use of PEG-rhG-CSF.
The Prophylactic use of PEG-rhG-CSF in the next cycle until FN or 4 grade neutropenia happened.
|
6mg (≥45kg) or 3mg (<45kg) i.h.
once 24h after chemotherapy in next cycle if FN or 4 grade neutropenia happened
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
FN rate
Time Frame: assessment at 1 month after the last cycle chemotherapy complete
|
rate of febrile neutropenia during all cycles of chemotherapy
|
assessment at 1 month after the last cycle chemotherapy complete
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
rate of 3-4 grade neutropenia
Time Frame: During all cycles of chemotherapy, through study completion, an average of half year
|
rate of 3-4 grade decrease of ANC
|
During all cycles of chemotherapy, through study completion, an average of half year
|
|
FN-caused hospitalization
Time Frame: During all cycles of chemotherapy, through study completion, an average of half year
|
rate of FN-caused hospitalization
|
During all cycles of chemotherapy, through study completion, an average of half year
|
|
FN-caused antibiotic use rate
Time Frame: During all cycles of chemotherapy, through study completion, an average of half year
|
rate of FN-caused antibiotic use
|
During all cycles of chemotherapy, through study completion, an average of half year
|
|
rate of dose reduction
Time Frame: During all cycles of chemotherapy, through study completion, an average of half year
|
rate of reduction of chemotherapy dose
|
During all cycles of chemotherapy, through study completion, an average of half year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Hongjian Yang, MD, Zhejiang Cancer Hospital
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RWS-PEGCSF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.